sCD4-17b bifunctional protein: Extremely broad and potent neutralization of HIV-1 Env pseudotyped viruses from genetically diverse primary isolates

Retrovirology

Volumn 7, Issue , 2010, Pages

  Lagenaur, Laurel A ^a   Villarroel, Vadim A ^a   Bundoc, Virgilio ^a   Dey, Barna ^a   Berger, Edward A ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; SOLUBLE CD4 ANTIGEN; SOLUBLE CD4 ANTIGEN 17B; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BIOLOGICAL PRODUCT; CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HYBRID PROTEIN; MONOCLONAL ANTIBODY;

ANTIBODY AFFINITY; ANTIGEN BINDING; ARTICLE; CLADISTICS; GENOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PROTEIN FUNCTION; VIRUS ISOLATION; VIRUS NEUTRALIZATION; VIRUS PARTICLE; DRUG EFFECT; GENETIC RECOMBINATION; GENETICS; IC 50; SERODIAGNOSIS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ANTI-HIV AGENTS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; BIOLOGICAL PRODUCTS; HIV ANTIBODIES; HIV-1; HUMANS; INHIBITORY CONCENTRATION 50; NEUTRALIZATION TESTS; RECOMBINANT FUSION PROTEINS; RECOMBINATION, GENETIC;

EID: 77949446701     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-7-11     Document Type: Article

References (60)

1. Wyatt R, Sodroski J. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. Science 1998, 280:1884-1888. 10.1126/science.280.5371.1884, 9632381.
2. Alkhatib G, Berger EA. HIV coreceptors: from discovery and designation to new paradigms and promise. Eur J Med Res 2007, 12:375-384.
3. Melikyan GB. Common principles and intermediates of viral protein-mediated fusion: the HIV-1 paradigm. Retrovirology 2008, 5:111. 10.1186/1742-4690-5-111, 2633019, 19077194.
4. Wyatt R, Kwong PD, Desjardins E, Sweet RW, Robinson J, Hendrickson WA, Sodroski JG. The antigenic structure of the HIV gp120 envelope glycoprotein. Nature 1998, 393:705-711. 10.1038/31514, 9641684.
5. Pantophlet R, Burton DR. gp120: target for neutralizing HIV-1 antibodies. Ann Rev Immunol 2006, 24:739-769.
6. Phogat S, Wyatt RT, Hedestam GBK. Inhibition of HIV-1 entry by antibodies: potential viral and cellular targets. J Internal Med 2007, 262:26-43. 10.1111/j.1365-2796.2007.01820.x, 2367133, 17598813.
7. Montefiori D, Sattentau Q, Flores J, Esparza J, Mascola J. Antibody-based HIV-1 vaccines: recent developments and future directions. PLoS Med 2007, 4:1867-1871.
8. Kwong PD, Wilson IA. HIV-1 and influenza antibodies: seeing antigens in new ways. Nature Immunol 2009, 10:573-578.
9. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, Steenbeke TD, Venturi M, Chaiken I, Fung M, Katinger H, Parren PW, Robinson J, Van Ryk D, Wang L, Burton DR, Freire E, Wyatt R, Sodroski J, Hendrickson WA, Arthos J. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002, 420:678-682. 10.1038/nature01188, 12478295.
10. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998, 393:648-659. 10.1038/31405, 9641677.
11. Kwong PD, Wyatt R, Majeed S, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structures of HIV-1 gp120 envelope glycoproteins from laboratory-adapted and primary isolates. Structure 2000, 8:1329-1339. 10.1016/S0969-2126(00)00547-5, 11188697.
12. Rizzuto CD, Wyatt R, Hernandez-Ramos N, Sun Y, Kwong PD, Hendrickson WA, Sodroski J. A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science 1998, 280:1949-1953. 10.1126/science.280.5371.1949, 9632396.
13. Rizzuto C, Sodroski J. Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120. AIDS Res Hum Retrovir 2000, 16:741-749. 10.1089/088922200308747, 10826481.
14. Myszka DG, Sweet RW, Hensley P, Brigham-Burke M, Kwong PD, Hendrickson WA, Wyatt R, Sodroski J, Doyle ML. Energetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci USA 2000, 97:9026-9031. 10.1073/pnas.97.16.9026, 16815, 10922058.
15. Chen B, Vogan EM, Gong HY, Skehel JJ, Wiley DC, Harrison SC. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 2005, 433:834-841. 10.1038/nature03327, 15729334.
16. Decker JM, Bibollet-Ruche F, Wei XP, Wang SY, Levy DN, Wang WQ, Delaporte E, Peeters M, Derdeyn CA, Allen S, Hunter E, Saag MS, Hoxie JA, Hahn BH, Kwong PD, Robinson JE, Shaw GM. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 2005, 201:1407-1419. 10.1084/jem.20042510, 2213183, 15867093.
17. Varadarajan R, Sharma D, Chakraborty K, Patel M, Citron M, Sinha P, Yadav R, Rashid U, Kennedy S, Eckert D, Geleziunas R, Bramhill D, Schleif W, Liang X, Shiver J. Characterization of gp120 and its single-chain derivatives, gp120-CD4(D12) and gp120-M9: Implications for targeting the CD4(i) epitope in human immunodeficiency virus vaccine design. Journal of Virology 2005, 79:1713-1723. 10.1128/JVI.79.3.1713-1723.2005, 544110, 15650196.
18. DeVico A, Fouts T, Lewis GK, Gallo RC, Godfrey K, Charurat M, Harris I, Galmin L, Pal R. Antibodies to CD4-induced sites in HIV gp120 correlate with the control of SHIV challenge in macaques vaccinated with subunit immunogens. Proc Natl Acad Sci USA 2007, 104:17477-17482. 10.1073/pnas.0707399104, 2077281, 17956985.
19. Dey B, Svehla K, Xu L, Wycuff D, Zhou TQ, Voss G, Phogat A, Chakrabarti BK, Li YX, Shaw G, Kwong PD, Nabel GJ, Mascola JR, Wyatt RT. Structure-based stabilization of HIV-1 gp120 enhances humoral immune responses to the induced co-receptor binding site. Plos Pathogens 2009, 5(5):e1000445. 10.1371/journal.ppat.1000445, 2680979, 19478876.
20. Thali M, Moore JP, Furman C, Charles M, Ho DD, Robinson J, Sodroski J. Characterization of conserved human immunodeficiency virus type-1 (HIV-1) gp120 neutralization epitopes exposed upon gp120-CD4 binding. J Virol 1993, 67:3978-3988. 237765, 7685405.
21. Gershoni JM, Denisova G, Raviv D, Smorodinsky NI, Buyaner D. HIV binding to Its receptor creates specific epitopes for the CD4/gp120 domplex. FASEB J 1993, 7:1185-1187.
22. Xiang SH, Doka N, Choudhary RK, Sodroski J, Robinson JE. Characterization of CD4-induced epitopes on the HIV type 1 gp120 envelope glycoprotein recognized by neutralizing human monoclonal antibodies. AIDS Res Hum Retrovirus 2002, 18:1207-1217.
23. Xiang SH, Wang LP, Abreu M, Huang CC, Kwong PD, Rosenberg E, Robinson JE, Sodroski J. Epitope mapping and characterization of a novel CD4-induced human monoclonal antibody capable of neutralizing primary hiv-1 strains. Virology 2003, 315:124-134. 10.1016/S0042-6822(03)00521-X, 14592765.
24. Choe H, Li WH, Wright PL, Vasilieva N, Venturi M, Huang CC, Grundner C, Dorfman T, Zwick MB, Wang LP, Rosenberg ES, Kwong PD, Burton DR, Robinson JE, Sodroski JG, Farzan M. Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of hiv-1 gp120. Cell 2003, 114:161-170. 10.1016/S0092-8674(03)00508-7, 12887918.
25. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, Borsetti A, Cardoso AA, Desjardin E, Newman W, Gerard C, Sodroski J. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996, 384:179-183. 10.1038/384179a0, 8906795.
26. Trkola A, Dragic T, Arthos J, Binley JM, Olson WC, Allaway GP, Cheng-Mayer C, Robinson J, Maddon PJ, Moore JP. CD4-dependent antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996, 384:184-187. 10.1038/384184a0, 8906796.
27. Sullivan N, Sun Y, Sattentau Q, Thali M, Wu D, Denisova G, Gershoni J, Robinson J, Moore J, Sodroski J. CD4-induced conformational changes in the human immunodeficiency virus type 1 gp120 glycoprotein: Consequences for virus entry and neutralization. J Virol 1998, 72:4694-4703. 109994, 9573233.
28. Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, Franti M, Binley J, Vivona V, Grundner C, Huang CC, Venturi M, Petropoulos CJ, Wrin T, Dimitrov DS, Robinson J, Kwong PD, Wyatt RT, Sodroski J, Burton DR. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gpl120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003, 77:10557-10565. 10.1128/JVI.77.19.10557-10565.2003, 228502, 12970440.
29. Dey B, Del Castillo CS, Berger EA. Neutralization of human immunodeficiency virus type 1 by sCD4-17b, a single-chain chimeric protein, based on sequential interaction of gp120 with CD4 and coreceptor. J Virol 2003, 77:2859-2865. 10.1128/JVI.77.5.2859-2865.2003, 149752, 12584309.
30. Louder MK, Sambor A, Chertova E, Hunte T, Barrett S, Ojong F, Sanders-Buell E, Zolla-Pazner S, McCutchan FE, Roser JD, Gabuzda D, Lifson JD, Mascola JR. HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity. Virology 2005, 339:226-238. 10.1016/j.virol.2005.06.003, 16005039.
31. Molday RS, Mackenzie D. Monoclonal antibodies to rhodopsin - characterization, cross-reactivity, and application as structural probes. Biochemistry 1983, 22:653-660. 10.1021/bi00272a020, 6188482.
32. Barouch DH, Yang ZY, Kong WP, Korioth-Schmitz B, Sumida SM, Truitt DM, Kishko MG, Arthur JC, Miura A, Mascola JR, Letvin NL, Nabel GJ. A human T-cell leukemia virus type 1 regulatory element enhances the immunogenicity of human immunodeficiency virus type 1 DNA vaccines in mice and nonhuman primates. J Virol 2005, 79:8828-8834. 10.1128/JVI.79.14.8828-8834.2005, 1168733, 15994776.
33. Oprian DD, Molday RS, Kaufman RJ, Khorana HG. Expression of a synthetic bovine rhodopsin gene in monkey kidney cells. Proc Natl Acad Sci USA 1987, 84:8874-8878. 10.1073/pnas.84.24.8874, 299653, 2962193.
34. Montefiori DC. Evaluating neutralizing antibodies against HIV, SIV, and SHIV in luciferase reporter gene assays. Curr Prot Immunol, Unit 12.11 2004, (Suppl 64):12.11.11-12.11.17. New York: John Wiley & Sons, Inc, Coligan JE, Kruisbeek AM, Margulies DH, Shevach EM, Strober W.
35. Kimpton J, Emerman M. Detection of replication-competent and pseudotyped human immunodeficiency virus with a sensitive cell line on the basis of activation of an integrated beta-galactosidase gene. J Virol 1992, 66:2232-2239. 289016, 1548759.
36. Chackerian B, Long EM, Luciw PA, Overbaugh J. Human immunodeficiency virus type 1 coreceptors participate in postentry stages in the virus replication cycle and function in simian immunodeficiency virus infection. J Virol 1997, 71:3932-3939. 191545, 9094670.
37. Polonis VR, Brown BK, Borges AR, Zolla-Pazner S, Dimitrov DS, Zhang MY, Barnett SW, Ruprecht RM, Scarlatti G, Fenyö EM, Montefiori DC, McCutchan FE, Michael NL. Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 2008, 375:315-320. 10.1016/j.virol.2008.02.007, 18367229.
38. Fenyö EM, Heath A, Dispinseri S, Holmes H, Lusso P, Zolla-Pazner S, Donners H, Heyndrickx L, Alcami J, Bongertz V, Jassoy C, Malnati M, Montefiori D, Moog C, Morris L, Osmanov S, Polonis V, Sattentau Q, Schuitemaker H, Sutthent R, Wrin T, Scarlatti G. International network for comparison of HIV neutralization assays: the NeutNet report. PLoS ONE 2009, 4:e4505. 10.1371/journal.pone.0004505, 2640999, 19229336.
39. Li M, Gao F, Mascola JR, Stamatatos L, Polonis VR, Koutsoukos M, Voss G, Goepfert P, Gilbert P, Greene KM, Bilska M, Kothe DL, Salazar-Gonzalez JF, Wei X, Decker JM, Hahn BH, Montefiori DC. Human immunodeficiency virus type 1 env clones from acute and early subtype B infections for standardized assessments of vaccine-elicited neutralizing antibodies. J Virol 2005, 79:10108-10125. 10.1128/JVI.79.16.10108-10125.2005, 1182643, 16051804.
40. Li M, Salazar-Gonzalez JF, Derdeyn CA, Morris L, Williamson C, Robinson JE, Decker JM, Li YY, Salazar MG, Polonis VR, Mlisana K, Karim SA, Hong K, Greene KM, Bilska M, Zhou J, Allen S, Chomba E, Mulenga J, Vwalika C, Gao F, Zhang M, Korber BT, Hunter E, Hahn BH, Montefiori D. Genetic and neutralization properties of subtype c human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in southern africa. J Virol 2006, 80:11776-11790. 10.1128/JVI.01730-06, 1642599, 16971434.
41. Blish CA, Nedellec R, Mandaliya K, Mosier DE, Overbaugh J. HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry. AIDS 2007, 21:693-702. 10.1097/QAD.0b013e32805e8727, 17413690.
42. Salzwedel K, Smith ED, Dey B, Berger EA. Sequential CD4-coreceptor interactions in human immunodeficiency virus type 1 Env function: soluble CD4 activates Env for coreceptor-dependent fusion and reveals blocking activities of antibodies against cryptic conserved epitopes on gp120. J Virol 2000, 74:326-333. 10.1128/JVI.74.1.326-333.2000, 111543, 10590121.
43. Blish CA, Blay WA, Haigwood NL, Overbaughl J. Transmission of HIV-1 in the face of neutralizing antibodies. Curr HIV Res 2007, 5:578-587. 10.2174/157016207782418461, 18045114.
44. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, , Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. Protocol G Principal Investigators Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 2009, 326:285-289. 10.1126/science.1178746, 19729618, Protocol G Principal Investigators.
45. Calarese DA, Scanlan CN, Zwick MB, Deechongkit S, Mimura Y, Kunert R, Zhu P, Wormald MR, Stanfield RL, Roux KH, Kelly JW, Rudd PM, Dwek RA, Katinger H, Burton DR, Wilson IA. Antibody domain exchange is an immunological solution to carbohydrate cluster recognition. Science 2003, 300:2065-2071. 10.1126/science.1083182, 12829775.
46. Wei XP, Decker JM, Wang SY, Hui HX, Kappes JC, Wu XY, Salazar-Gonzalez JF, Salazar MG, Kilby JM, Saag MS, Komarova NL, Nowak MA, Hahn BH, Kwong PD, Shaw GM. Antibody neutralization and escape by HIV-1. Nature 2003, 422:307-312. 10.1038/nature01470, 12646921.
47. Willey RL, Shibata R, Freed EO, Cho MW, Martin MA. Differential glycosylation, virion incorporation, and sensitivity to neutralizing antibodies of human immunodeficiency virus type 1 envelope produced from infected primary T-lymphocyte and macrophage cultures. J Virol 1996, 70:6431-6436. 190674, 8709276.
48. Stiegler G, Katinger H. Therapeutic potential of neutralizing antibodies in the treatment of HIV-1 infection. J Antimicrob Chemother 2003, 51:757-759. 10.1093/jac/dkg172, 12654737.
49. Johnson PR, Schnepp BC, Zhang JC, Connell MJ, Greene SM, Yuste E, Desrosiers RC, Clark KR. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med 2009, 15:901-U999. 10.1038/nm.1967, 2723177, 19448633.
50. Luo XM, Maarschalk E, O'Connell RM, Wang P, Yang LL, Baltimore D. Engineering human hematopoietic stem/progenitor cells to produce a broadly neutralizing anti-HIV antibody after in vitro maturation to human B lymphocytes. Blood 2009, 113:1422-1431. 10.1182/blood-2008-09-177139, 19059876.
51. Jacobson JM, Israel RJ, Lowy I, Ostrow NA, Vassilatos LS, Barish M, Tran DNH, Sullivan BM, Ketas TJ, O'Neill TJ, Nagashima KA, Huang W, Petropoulos CJ, Moore JP, Maddon PJ, Olson WC. Treatment of advanced human immunodeficiency virus type 1 disease with the viral entry inhibitor pro 542. Antimicrobial Agents and Chemotherapy 2004, 48:423-429. 10.1128/AAC.48.2.423-429.2004, 321533, 14742190.
52. Lederman MM, Jump R, Pilch-Cooper HA, Root M, Sieg SF. Topical application of entry inhibitors as "virustats" to prevent sexual transmission of HIV infection. Retrovirology 2008, 5:116. 10.1186/1742-4690-5-116, 2637900, 19094217.
53. Zeitlin L, Pauly M, Whaley KJ. Second-generation HIV microbicides: Continued development of griffithsin. Proc Natl Acad Sci USA 2009, 106:6029-6030. 10.1073/pnas.0902239106, 2669335, 19357305.
54. O'Keefe BR, Vojdani F, Buffa V, Shattock RJ, Montefiori DC, Bakke J, Mirsalis J, d'Andrea AL, Hume SD, Bratcher B, Saucedo CJ, McMahon JB, Pogue GP, Palmer KE. Scaleable manufacture of HIV-1 entry inhibitor griffithsin and validation of its safety and efficacy as a topical microbicide component. Proc Natl Acad Sci USA 2009, 106:6099-6104. 10.1073/pnas.0901506106, 2662964,2662964, 19332801.
55. Wells JM, Mercenier A. Mucosal delivery of therapeutic and prophylactic molecules using lactic acid bacteria. Nature Rev Microbiol 2008, 6:349-362.
56. Chang TLY, Chang CH, Simpson DA, Xu Q, Martin PK, Lagenaur LA, Schoolnik GK, Ho DD, Hillier SL, Holodniy M, Lewicki JA, Lee PP. Inhibition of HIV infectivity by a natural human isolate of Lactobacillus jensenii engineered to express functional two- domain CD4. Proc Natl Acad Sci USA 2003, 100:11672-11677. 10.1073/pnas.1934747100, 208816, 12972635.
57. Liu XM, Lagenaur LA, Lee PP, Xu Q. Engineering of a human vaginal Lactobacillus strain for surface expression of two-domain CD4 molecules. Appl Environ Microbiol 2008, 74:4626-4635. 10.1128/AEM.00104-08, 2504410,2504410, 18539799.
58. Rao S, Hu S, McHugh L, Lueders K, Henry K, Zhao Q, Fekete RA, Kar S, Adhya S, Hamer DH. Toward a live microbial microbicide for HIV: commensal bacteria secreting an HIV fusion inhibitor peptide. Proc Natl Acad Sci USA 2005, 102:11993-11998. 10.1073/pnas.0504881102, 1189328, 16040799.
59. Liu XW, Lagenaur LA, Simpson DA, Essenmacher KP, Frazier-Parker CL, Liu Y, Tsai D, Rao SS, Hamer DH, Parks TP, Lee PP, Xu Q. Engineered vaginal Lactobacillus strain for mucosal delivery of the human immunodeficiency virus inhibitor cyanovirin-N. Antimicrob Agents Chemother 2006, 50:3250-3259. 10.1128/AAC.00493-06, 1610104, 17005802.
60. Liu JJ, Reid G, Jiang YH, Turner MS, Tsai CC. Activity of HIV entry and fusion inhibitors expressed by the human vaginal colonizing probiotic Lactobacillus reuteri RC-14. Cell Microbiol 2007, 9:120-130. 10.1111/j.1462-5822.2006.00772.x, 16879452.